Incyte Corporation - Common Stock (INCY)

Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside the launch traction of Niktimvo, as major contributors to the quarter’s strong operational performance. CEO William Meury emphasized the company’s ongoing cost discipline and strategic investment in core R&D programs. He noted, “Our job right now is to keep [the fundamentals] that way and to identify effective ways to optimize the promotional strategies and investment for these products to drive future growth.”

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. 

Incyte (INCY) Q3 2025 Earnings Call Transcript

The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit.

Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.

INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity.

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic dermatitis in children. 

JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the company's shares. On October 9, 2025, JPMorgan analyst Jessica Fye increased Incyte's price target to $89.00, a significant jump from

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index.